Thrombosis
From the Journals
Daily aspirin linked to increased risk of heart failure
Daily aspirin may need to be reconsidered in those at risk of heart failure, based on evidence of an association.
Conference Coverage
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a...
Latest News
Exercise reduces arm and shoulder problems after breast cancer surgery
Study provides the best quality evidence to date in support of early exercise for women at high risk of shoulder problems after breast cancer...
Conference Coverage
PRAGUE-17: LAA closure holds up against DOACs out to 4 years
Most outcomes remained unchanged, but follow-up imaging curtailed by the COVID-19 pandemic leaves an unfortunate gap with regard to late device-...
Conference Coverage
CABG safe 3 days after stopping ticagrelor: RAPID CABG
A new randomized trial showed similar rates of severe bleeding in patients going to surgery at 3 days and 6 days after stopping the antiplatelet...
Conference Coverage
Direct comparison shows differing strengths for left atrial closure devices
For left atrial appendage closure, differences are found between the Amplatzer Amulet and the Watchman FLX in randomized trials.
Conference Coverage
Short DAPT course beneficial after PCI in ‘bi-risk’ patients
MASTER DAPT subgroup analysis supports short antiplatelet course in cases of high bleeding and ischemic risk.
From the Journals
Antithrombotic therapy not warranted in COVID-19 outpatients
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI...
Conference Coverage
Estimating insulin resistance may help predict stroke, death in T2D
The estimated glucose disposal rate may be useful way to determine first stroke risk in type 2 diabetes.
From the Journals
D-dimer unreliable for ruling out pulmonary embolism in COVID-19
From the Journals
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.